Vicki Batts Reports:
While you’d be hard pressed to find anyone willing to use a known herbicide for medicinal purposes, that hasn’t stopped Monsanto from patenting the star ingredient of their flagship herbicide, Roundup, as a type of antibiotic. In 2003, the corporate giant first submitted a patent for glyphosate as a parasitic control-type antimicrobial agent — or, in other words, a type of antibiotic.
The patent was granted in 2010, and you can view it here. Monsanto patented the combination of glyphosate and polyvalent anion oxalic acid as a method for preventing and treating pathogenic infections like malaria. As the patent explains, parasites from the phylum of Apicomplexa are often responsible for diseases in humans and other animals — and glyphosate is capable of inhibiting the growth of these parasites.
This patent certainly brings even more concerns about the impending Bayer-Monsanto merger, but more importantly, it raises a significant question: is glyphosate contributing to the proliferation of antibiotic-resistant bacteria?